Latest posts
-
Exosomes in Non-Alcoholic Steatohepatitis: Reversing Hepatocyte Lipotoxicity and Fibrogenesis Through Extracellular Vesicle Therapy
Non-alcoholic steatohepatitis (NASH), now renamed MASH, has become the fastest-growing cause of liver transplantation. Affecting 20-25% of adults globally, the disease progresses silently from steatosis through inflammation, fibrosis, cirrhosis, and cancer. Approved drug options remain limited. Exosome-based therapy addresses both lipotoxic and fibrotic dimensions simultaneously. The Multi-Hit Pathogenesis Model Current understanding involves metabolic dysfunction, lipotoxicity,…